(NASDAQ: BCDA) Biocardia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.69%.
Biocardia's earnings in 2026 is -$7,775,000.On average, 4 Wall Street analysts forecast BCDA's earnings for 2026 to be -$7,599,453, with the lowest BCDA earnings forecast at -$7,914,533, and the highest BCDA earnings forecast at -$7,166,076. On average, 4 Wall Street analysts forecast BCDA's earnings for 2027 to be -$5,859,120, with the lowest BCDA earnings forecast at -$6,242,449, and the highest BCDA earnings forecast at -$5,374,557.
In 2028, BCDA is forecast to generate -$4,524,865 in earnings, with the lowest earnings forecast at -$4,458,892 and the highest earnings forecast at -$4,538,515.